Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...

NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.

Patients took each of four doses for seven days, resulting in average daily doses of 9.25 mg and 18 mg ... found last year when it linked its oral amylin and GLP-1 receptor co-agonist amycretin ...

CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide (2.4 mg) and semaglutide (2.4 ... which also fell short of the expected loss of 25%. NVO plans to file regulatory ...

Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy, the diabetes and obesity treatments, revealed data showing that its new weight-loss drug candidate ...

CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide (2.4 mg) and semaglutide (2.4 ... which also fell short of the expected loss of 25%. NVO plans to file regulatory ...

First of all, it is in the process of developing a long-acting subcutaneous amylin analog drug to treat ... Index [BMI] of greater than or equal to 25 Obese - Classified as having a BMI of greater ...

Cagrilintide acts like a hormone called amylin that your ... with a high dose (1.2 mg or more, twice a week) lost 5% or more of their starting weight, and over 25% lost 10% or more of their ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.